

See discussions, stats, and author profiles for this publication at: <https://www.researchgate.net/publication/265642130>

De novo asymmetric synthesis of the mezzettiaside family of natural products via the iterative use of a dual B-/Pd-catalyzed glycosylation

ARTICLE *in* CHEMICAL SCIENCE · FEBRUARY 2014

Impact Factor: 9.21 · DOI: 10.1039/c4sc00593g

CITATIONS

9

READS

19

4 AUTHORS, INCLUDING:



Sumit Bajaj

The Scripps Research Institute

4 PUBLICATIONS 11 CITATIONS

SEE PROFILE



Ehesan U Sharif

Stanford University

10 PUBLICATIONS 80 CITATIONS

SEE PROFILE



George A O'Doherty

Northeastern University

208 PUBLICATIONS 3,314 CITATIONS

SEE PROFILE

De novo asymmetric synthesis of the mezzettiaside family of natural products via the iterative use of a dual B-/Pd-catalyzed glycosylation†

Cite this: DOI: 10.1039/c4sc00593g

Sumit O. Bajaj,^a Ehesan U. Sharif,^{*a} Novruz G. Akhmedov^{*b} and George A. O'Doherty^{*a}

Received 25th February 2014
Accepted 14th March 2014

DOI: 10.1039/c4sc00593g

www.rsc.org/chemicalscience

The first synthesis of any and all members of the mezzettiaside family of natural products has been achieved. The reported synthesis features the iterative use of the Taylor catalyst in a dual nucleophilic boron/ electrophilic palladium catalyzed regioselective glycosylation. In addition, the *de novo* approach utilizes atomless protecting groups and the minimal use of protecting groups (2 chloroacetates for the synthesis of 10 natural products). These divergent syntheses occurred in a range of 13–22 longest linear steps and required only 41 total steps to prepare the entire family of mezzettiasides.

Introduction

The mezzettiasides are a family of partially acetylated oligorhamnose natural products that were isolated from the fruit and bark of several medicinally relevant *Mezzettia leptopoda* Annonaceae plants located in the Malaysian island of Borneo.¹ These anticancer natural products were shown to consist of α -1,3-linked *L*-rhamno-di-, tri- and tetra-saccharides with differing patterns of acetylation (Fig. 1). Initial testing of the mezzettiasides revealed their $\mu\text{g mL}^{-1}$ cytotoxicity against three human cell lines (KB, Col2 and Lu1).²

As part of a program aimed at the synthesis and biological investigation of anticancer/antibiotic oligosaccharide natural products,³ we became interested in the synthesis of mezzettiasides. This interest came out of our synthesis and study of a related class of tri- and tetrasaccharide natural products, the cleistriosides and cleistetrosides,⁴ where we found the pattern of acetylation had a significant effect on the biological activity. As a continuation of these studies, we desired access to all ten members of the mezzettiaside natural products. While re-isolation of these materials from the various sources was considered, we instead decided upon a *de novo* asymmetric synthetic approach,⁵ as this approach would nicely position us for further structure activity relationship (SAR) studies.⁶ We were particularly intrigued at the possibility of efficiently assembling all members of the mezzettiasides *via* a divergent approach that would minimize the use of protecting groups. Herein, we disclose our successful *de novo* asymmetric approach to all ten members of the mezzettiaside where all the stereocenters in the represented natural products were derived from achiral acetyl furan (1).

Retrosynthetically, we envisioned that the three tetrasaccharide (5–7) and the four trisaccharide (2–4 & 8) mezzettiasides could be obtained from a common pyranone containing trisaccharide intermediate 13 (Scheme 1). In turn, trisaccharide 13 as well as, the three disaccharide natural products (9–11) could be prepared from pyran containing rhamnoside 12. Finally allylic alcohol 12 could be obtained from achiral 2-acetyl furan (1) using our *de novo* approach to carbohydrates.⁷ Key to the success of this approach is the strategic use of atomless/minimal protecting groups (enone of a pyranone as a masked triol and a chloroacetate as the only protecting group) in combination with the iterative use of a highly stereo- and regio-selective organoboron/Pd-catalyzed glycosylation (*i.e.*, a dual nucleophilic/electrophilic catalysis).^{8,9}





Fig. 1 The mezzettiaside family of natural products.

^aDepartment of Chemistry and Chemical Biology, Northeastern University, Boston, MA 02115, USA. E-mail: G.O'Doherty@neu.edu; Web: <http://www.as.wvu.edu/~odoherty/site/>

^bDepartment of Chemistry, West Virginia University, Morgantown, WV 26506, USA

† Electronic supplementary information (ESI) available: Experimental procedures, ¹H and ¹³C NMR spectra and correlation studies. See DOI: 10.1039/c4sc00593g




Scheme 1 Retrosynthetic analysis of mezzettiasides.

Results and discussion

Our synthesis began with pyranone **14**, which can be prepared in optically pure form in 3 steps from achiral furan **1**.¹⁰ Glycosylation of 1-octanol with pyranone **14** using our typical conditions ($\text{Pd}_2(\text{dba})_3 \cdot \text{CHCl}_3/4\text{PPh}_3$ in CH_2Cl_2)⁶ gave enone **15** (93%). Luche reduction ($\text{NaBH}_4/\text{CeCl}_3$) of enone **15** gave allylic alcohol **16** (80%). The C-4 hexanoate ester was installed by a Steglich esterification ($\text{DCC}/\text{C}_5\text{H}_{11}\text{CO}_2\text{H}/\text{DMAP}$) and an Upjohn dihydroxylation ($\text{OsO}_4/\text{NMO}(\text{aq})$) was used to diastereoselectively install the C-2/3 *rhamno*-stereochemistry (**16** to **17a**) (75%, 2 steps) (Scheme 2).¹¹

We next investigated on a catalytic regio-/stereoselective glycosylation of the C-3 hydroxyl of **17a**. When the Pd-glycosylation was performed on diol **17a**, a 1 : 2 mixture of regioisomer (C-3 vs. C-2) was produced. Previously, we have found that the tin acetal of similar diols can react regioselectively ($\sim 7 : 1$)



Scheme 2 Synthesis of key disaccharide intermediate 12.

Table 1 Boron vs. Tin mediated regioselective glycosylation

Additive	solvent(s)	19:20	yield	
none	CH_2Cl_2	1:2	61%	
$\text{Bu}_2\text{Sn}=\text{O}$ (1.1 equiv)	CH_2Cl_2	5:1	68%	
Boron cat. (15 mol%)	CH_2Cl_2	2.5:1	61%	
Boron cat. (10 mol%)	$\text{CH}_3\text{CN}/\text{CH}_2\text{Cl}_2$ (1:0.2)	3:1	65%	
Boron cat. (15 mol%)	$\text{CH}_3\text{CN}/\text{THF}$ (1:0.1)	6:1	74%	
Boron cat. (30 mol%)	$\text{CH}_3\text{CN}/\text{THF}$ (1:0.1)	7.5:1	77%	

under similar Pd-glycosylation conditions.⁴ The tin acetal **17b** formation, however, was difficult to optimize, as conversion to the crude tin acetal must be complete to get good yields and regioselectivities. When this 2-step procedure was performed under optimal conditions, a 5 : 1 mixture of C-3 to C-2 regioisomers was obtained (68%) (Table 1).

A practical alternative to this difficult to execute procedure emerged when we replaced the stoichiometric tin reagent with the catalytic boron reagent developed by Taylor ($\text{Ph}_2\text{BOCH}_2\text{CH}_2\text{NH}_2$) resulting in a dual B-nucleophilic/Pd-electrophilic catalyzed glycosylation.^{12,13} For instance, when the Taylor catalyst was added to our typical glycosylation conditions (2.5% $\text{Pd}_2(\text{dba})_3 \cdot \text{CHCl}_3/4\text{PPh}_3$, 15 mol% $\text{Ph}_2\text{BOCH}_2\text{CH}_2\text{NH}_2$ in CH_2Cl_2) a 2.5 : 1 mixture of C-3 to C-2 regioisomers was obtained. This ratio was significantly increased to 6 : 1, when the solvent system was changed from CH_2Cl_2 to $\text{CH}_3\text{CN}/\text{THF}$ (10 : 1). Varying the percentage of the boron catalyst from 10 to 30 percent found the optimal B/Pd ratio to be 6 : 1 for this glycosylation reaction. Presumably the anionic nature of the borinate complex **17c** makes it an ideal coupling partner with the cationic Pd- π -allyl complex (e.g., intermediate **18**, Fig. 2), whereas the more polar solvent improves the turnover rate for the formation of borinate **17c**. Thus, rendering it significantly more reactive than the neutral diol **17a** and as a result requiring on catalytic amounts to impart excellent regiocontrol.

Under our optimized conditions (2.5 mol% $\text{Pd}_2(\text{dba})_3 \cdot \text{CHCl}_3/4\text{PPh}_3$, 30 mol% $\text{Ph}_2\text{BOCH}_2\text{CH}_2\text{NH}_2$ in $\text{CH}_3\text{CN}/\text{THF}$ (10 : 1)) a mixture of **17a/14** (1 : 1.1) was coupled in





Fig. 2 Plausible transition state for glycosylation via dual catalysis.



Scheme 3 Synthesis of mezzettiaside-9, 10 & 11.

an 77% yield with good regiocontrol (7.5 : 1). It is worth noting that when the C-4 ester is smaller (e.g., OAc), significantly better regiocontrol (16 : 1) was observed in this B-/Pd-dual catalyzed glycosylation (e.g., 23 to 24, Scheme 5). The mixture of regioisomeric products 19 and 20 was difficult to separate at preparative scales. This was easily solved by protecting the remaining hydroxyl group 19 and 20 as a chloroacetate (21) and reducing the enone to give pure allylic alcohol 12 in 85% after silica gel chromatography.


The allylic alcohol portion of 12 could be easily elaborated into the three disaccharide members of the mezzettiasides 9–11 (Scheme 3). Synthesis of mezzettiaside-9 was accomplished in four steps (64%). Specifically, the allylic alcohol 12 underwent chloroacetylation at the C-4 position ($(\text{ClAc})_2\text{O}$, 10 mol% DMAP in Py), followed by an Upjohn dihydroxylation ($\text{OsO}_4/\text{NMO}(\text{aq})$), bis-acetylation ($\text{Ac}_2\text{O}/\text{Py}$) and finally bis-deprotection of the two chloroacetate groups (thiourea, NaHCO_3 and $n\text{-Bu}_4\text{NI}$)¹⁴ to give mezzettiaside-9. When the chloroacetylation step was removed from the above sequence, the resulting three steps sequence provides mezzettiaside-11, in overall good yield (66%). The regioisomeric diacetate mezzettiaside-10 was prepared by a slightly different sequence. The allylic alcohol 12 was C-4 acetylated, dihydroxylated, and regioselectively acetylated *via* orthoester formation to give the protected disaccharide 22 (68%, 3 steps). Once again, selective removal to the C-2 chloroacetate group gave mezzettiaside-10 (86%). In addition to being an intermediate for the synthesis of mezzettiaside-10, disaccharide 22 proved to be the launching point for the syntheses of the remaining tri- and tetrasaccharide members of the mezzettiasides (Schemes 4–6).

The application of this approach to the trisaccharide mezzettiasides 2–4 and 8, began with the Pd-catalyzed glycosylation of disaccharide 22 with pyranone 14 to give trisaccharide 13 (68%). A four step post glycosylation sequence was used to


convert trisaccharide 13 into mezzettiaside 8. This involved a two-step post-glycosylation transformation ($\text{NaBH}_4/\text{CeCl}_3$ and $\text{OsO}_4/\text{NMO}(\text{aq})$) of the enone functionality of 13 into a *rhamno*-sugar, an orthoester mediated axial acetylation at C-2 followed by chloroacetate deprotection to give mezzettiaside 8 (53%, 4 steps).

The key tris-*rhamno*-trisaccharide intermediate 23 for the synthesis of mezzettiaside 2, 3 and 4 was synthesized from trisaccharide 13 by incorporating a C-4 acetylation into the above post-glycosylation sequence ($\text{NaBH}_4/\text{CeCl}_3$, $\text{Ac}_2\text{O}/\text{Py}$ and $\text{OsO}_4/\text{NMO}(\text{aq})$), (Scheme 4). Mezzettiaside 4 was obtained by removing the chloroacetate protecting group (23 to 4, 82%). The required C-2 acetylation in mezzettiaside 2 was achieved *via* orthoester while the C-3 acetate for mezzettiaside 3 was obtained *via* Taylor borinate catalyzed acetylation of 23.¹⁰ Finally removal of chloroacetate gave mezzettiaside 2 and mezzettiaside 3 in 64% and 58% overall yield respectively (Scheme 4).

As with disaccharide 22, trisaccharide 23 served as a point of divergence for the route to the final three tetrasaccharide mezzettiasides 5–7 (Scheme 5). The route to the tetrasaccharide natural products began with a second regioselective C-3 glycosylation (23 and 14). This was accomplished once again with use of the Taylor catalyst in the dual B-nucleophilic/Pd-electrophilic catalyzed glycosylation (2.5 mol% $\text{Pd}_2(\text{dba})_3 \cdot \text{CHCl}_3/4\text{PPh}_3$, 15




Scheme 4 Synthesis of mezzettiaside-2, 3, 4 & 8.



Scheme 5 Synthesis of mezzettiaside-5.

mol% Ph₂BOCH₂CH₂NH₂ in THF/CH₃CN) to give tetrasaccharide enone **24** in excellent yield 76%. In contrast to **17a** with a more hindered C-4 hexanoate, for diol **23** with a C-4 acetate, only 15 mol% boron catalyst was needed to achieve near complete regiocontrol (>16 : 1) in the glycosylation. The resulting enone was converted into a *rhamno*-sugar **25** by a successive Luche reduction and Upjohn dihydroxylation (73%, 2 steps). As before, a regioselective C-3 acetylation using catalytic borinate followed by chloroacetate deprotection converted compound **25** into mezzettiaside-5 (58%, 2 steps). In contrast, a C-2 acetylation *via* orthoester and a successive chloroacetate deprotection gave mezzettiaside-6 (**25** to **6**; 61%, 2 steps). Whereas, a direct chloroacetate deprotection of **25** provided the final tetrasaccharide natural product, mezzettiaside-7 (83%).

Comparison of the spectral data (¹H, ¹³C NMR) for synthetic mezzettiasides with the data reported for the isolated materials was complicated by the choice of mixed solvent systems (CD₃OD/C₆D₆) used in the isolation work. The same features that allow for increase resolution of the ¹H and ¹³C spectra from the use of CD₃OD/C₆D₆ also lead to the increased sensitivity to small changes in solvent ratio and water impurities. In addition, slightly different chemical shifts are obtained depending on which solvent is used as the reference standard. This problem with carbohydrate natural products has been previously observed by us¹⁵ and others.¹⁶ By exercising with great care in the solvent ratios we were able to generate ¹³C NMR spectra for nine of the ten mezzettiasides where the shifts fell within (+/–) 0.5 ppm. Unfortunately, for mezzettiaside **8**, we were unsuccessful at finding the identical solvent system to reproduce the spectra of the natural material. Using the reported ratio (CD₃OD : C₆D₆ (6 : 1)) the difference in ¹³C NMR shifts was as high as (+/–) 0.9 ppm. It should be noted that the multiplicities and coupling



Scheme 6 Synthesis of the tetrasaccharide mezzettiaside-6 & 7.

constants in ¹H NMR were in agreement with that found for the synthetic material and consistent with the structure reported. In order to confirm the 3D-structure of the synthetic material, a detailed NMR studies were conducted on synthetic mezzettiaside-**8** (see, ESI†) as well as mezzettiasides-**3** and **4**. Thus, we believe that the structure of the synthetic and isolated mezzettiaside-**8** are the same. In this regard, we recommend future comparisons to mezzettiaside NMR data should be to the CDCl₃ and C₆D₆ spectra for the mezzettiasides reported herein.

Conclusions

In conclusion, we have successfully completed the first total synthesis of any and all members of the mezzettiaside family of natural products. This divergent synthesis of all 10 mezzettiasides occurred in a range of 13 to 22 longest linear steps. A more notable measure of efficiency is that the entire family of natural products was prepared in only 41 total steps (~4 steps/natural product). This highly efficient, regio- and stereo-selective divergent synthesis relied on the strategic use of a novel dual B-/Pd-catalyzed glycosylation, which was used to construct two of the four-glycosidic bonds in progressively more complex settings. Additional efficiencies were achieved by the use of numerous regioselective acetylation as well as an atomless-protecting group strategy which minimized the number of protecting groups required to only two chloroacetate for 10 natural products. The synthesis was amenable for the preparation of significant quantities of each member of the mezzettiasides (5–15 mg) for further biological studies, which will be reported in due course.

Author contributions

S.O.B conducted all the synthetic work. N.G.A. was responsible for the NMR structure elucidation/confirmation. E.U.S. and G.A.O. provided guidance. All authors contributed to the preparation of the manuscript.

Acknowledgements

We are grateful to the NIH (GM088839) and NSF (CHE-0749451) for their generous support of our research program.

Notes and references

- (a) J. T. Etse, A. I. Gray, C. Lavaud, G. Massiot, J.-M. Nuzillard and P. G. Waterman, *J. Chem. Soc., Perkin Trans. 1*, 1991, 861; (b) D. A. Powell, W. S. York, H. V. Halbeek, J. T. Etse, A. I. Gray and P. G. Waterman, *Can. J. Chem.*, 1990, **68**, 1044–1050.
- B. Cui, H. Chai, T. Santisuk, V. Reutrakul, N. R. Farnsworth, G. A. Cordell, J. M. Pezzuto and A. D. Kinghorn, *J. Nat. Prod.*, 1998, **61**, 1535.
- P. Shi, M. C. Silva, H. L. Wang, N. G. Akhmedov, M. Li, P. J. Beuning and G. A. O'Doherty, *ACS Med. Chem. Lett.*, 2012, **3**(12), 1086.
- (a) D. Wu, M. Li and G. A. O'Doherty, *Org. Lett.*, 2010, **12**(23), 5466; (b) V. Seidel, F. Bailleul and P. G. Waterman, *J. Nat. Prod.*, 2000, **63**, 6.
- (a) S. Y. Ko, A. W. Lee, S. Masamune, L. A. Reed and K. B. Sharpless, *Science*, 1983, **220**, 949; (b) A. B. Northrup and D. W. C. MacMillan, *Science*, 2004, **305**, 1752; (c) Md. M. Ahmed, B. P. Berry, T. J. Hunter, D. J. Tomcik and G. A. O'Doherty, *Org. Lett.*, 2005, **7**, 745; (d) J. M. Harris, M. D. Keranen, H. Nguyen, V. G. Young and G. A. O'Doherty, *Carbohydr. Res.*, 2000, **328**, 17; (e) J. M. Harris, M. D. Keranen and G. A. O'Doherty, *J. Org. Chem.*, 1999, **64**, 2982–2983.
- (a) R. S. Babu and G. A. O'Doherty, *J. Am. Chem. Soc.*, 2003, **125**, 12406; (b) R. S. Babu, M. Zhou and G. A. O'Doherty, *J. Am. Chem. Soc.*, 2004, **126**, 3428; (c) R. S. Babu and G. A. O'Doherty, *J. Carbohydr. Chem.*, 2005, **24**, 169; (d) H. Guo and G. A. O'Doherty, *Angew. Chem., Int. Ed.*, 2007, **46**, 5206; (e) H. Guo and G. A. O'Doherty, *J. Org. Chem.*, 2008, **73**, 5211.
- (a) M. Li, J. G. Scott and G. A. O'Doherty, *Tetrahedron Lett.*, 2004, **45**, 1005; (b) H. Guo and G. A. O'Doherty, *Org. Lett.*, 2005, **7**, 3921.
- For an example of a dual catalyzed phosphine/Pd reactions, see: (a) B. G. Jellerichs, J.-R. Kong and M. J. Krische, *J. Am. Chem. Soc.*, 2003, **125**, 7758, for an example of Sn/Pd catalysis, see: (b) M. Kuriyama, T. Takeichi, M. Ito, N. Yamasaki, R. Yamamura, Y. Demizu and O. Onomura, *Chem.-Eur. J.*, 2012, **18**, 2477.
- For an example of a stepwise nucleophilic phosphine then Pd-catalyzed reactions, see: Y. Fan and O. Kwon, *Org. Lett.*, 2012, **14**, 3264.
- (a) M. Shan and G. A. O'Doherty, *Org. Lett.*, 2010, **12**, 2986; (b) M. Shan and G. A. O'Doherty, *Org. Lett.*, 2006, **8**, 5149; (c) R. Noyori, T. Ohkuma and M. Kitamura, *J. Am. Chem. Soc.*, 1987, **109**, 5856; (d) O. Achmatowicz, P. Bukowski, B. Szechner, Z. Zwierzchowska and A. Zamojski, *Tetrahedron*, 1971, **27**, 1973.
- In general, we have found the NaBH₄ (with and without CeCl₃) reduction of α -pyranones (**13**, **15**, **19** and **24**) and the OsO₄ catalyzed dihydroxylation of the resulting allylic alcohol (e.g., **12**, **16**) to proceed with virtually complete diastereocontrol, see ref. 4, 6, 7 and 10.
- (a) D. Lee and M. S. Taylor, *J. Am. Chem. Soc.*, 2011, **133**, 3724; (b) C. Gouliaras, D. Lee, L. Chan and M. S. Taylor, *J. Am. Chem. Soc.*, 2011, **133**, 13926; (c) C. A. McClary and M. S. Taylor, *Carbohydr. Res.*, 2013, **381**, 112; (d) E. Dimitrijevic and M. S. Taylor, *Chem. Sci.*, 2013, **4**, 3298; (e) T. M. Beale and M. S. Taylor, *Org. Lett.*, 2013, **15**, 1358.
- While the Taylor catalyst has been used in regioselective glycosylations (glycosylbromide with excess Ag₂O, ref. 12), this is the first example of its use to catalytically induce regiocontrol in a catalyzed glycosylation.
- (a) M. H. Clausen and R. Madsen, *Chem.-Eur. J.*, 2003, **9**, 3821–3832; (b) M. Naruto, K. Ohno and N. Takeuchi, *Tetrahedron Lett.*, 1979, 251.
- E. U. Sharif, H. L. Wang, N. G. Akhmedov and G. A. O'Doherty, *Org. Lett.*, 2014, **16**, 492.
- (a) T. Nagano, J. Pospisil, G. Chollet, S. Schulthoff, V. Hickmann, E. Moulin, J. Herrmann, R. Müller and A. Fürstner, *Chem.-Eur. J.*, 2009, **15**, 9697; (b) A. Molinaro, C. De Castro, R. Lanzetta, E. Manzo and M. J. Parrilli, *J. Am. Chem. Soc.*, 2001, **123**, 12605; (c) S. Bekiroglu, A. Sandström, L. Kenne and C. Sandström, *Org. Biomol. Chem.*, 2004, **2**, 200; (d) A. Kondoh, A. Arlt, B. Gabor and A. Fürstner, *Chem.-Eur. J.*, 2013, **19**, 7731.